Precigen Reported $53.1 Million Revenue for Papzimeos
The Germantown firm saw its immunotherapy drug for rare respiratory conditions generate significant sales in Q2 2026.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Should local governments prioritize investments to attract and expand the biotech industry in your area?
Biopharmaceutical firm Precigen generated $53.1 million in net revenue from its FDA-approved immunotherapy drug Papzimeos during the second quarter of 2026. The drug, which targets recurrent respiratory papillomatosis, received regulatory clearance in August 2025.
Why it matters
The company’s growth in the rare disease therapeutic space follows years of collaborative clinical development and ongoing local operational expansion in Germantown. This performance underscores the commercial viability of precision medicine approaches for treating difficult-to-manage rare conditions.
Precigen reported $53.1 million in net revenue for Papzimeos in Q2 2026, supported by a workforce of 175 employees as of July 2026.
The players
Precigen
A Germantown-based biopharmaceutical company specializing in the development of precision medicines for rare diseases.
National Institutes of Health
A federal medical research agency that collaborated with Precigen on clinical trials for Papzimeos from 2021 to 2024.
The details
Precigen develops precision medicines for rare diseases through research collaborations with the National Institutes of Health and regional universities. The company conducts clinical trials to validate treatment efficacy and has expanded its physical footprint in Germantown to meet manufacturing and operational demand.
Timeline
2021-2024: Clinical trials for Papzimeos were conducted in collaboration with the National Institutes of Health.
August 2025: Papzimeos received official FDA approval for clinical use.
July 2026: Precigen confirmed its total headcount reached 175 employees.
Q2 2026: The company generated $53.1 million in net revenue for Papzimeos.
The Tech Race
The success of Papzimeos represents the effective commercialization of a treatment pathway refined through a long-term research partnership with the National Institutes of Health. This trajectory illustrates the transition from public-private research clinical validation to sustained market demand.
The expansion of Precigen’s Germantown facility in response to drug demand highlights the growing local footprint of specialized biopharmaceutical manufacturing. Patients and medical providers benefit from the availability of Papzimeos for recurrent respiratory papillomatosis.
The takeaway
Precigen’s revenue performance highlights the commercial potential of specialized immunotherapies developed through federal research partnerships. Observers should track the company’s future filings to monitor if this growth trajectory in rare disease treatment persists.
Further reading
For more on local research and industry trends, visit Biotech.
Source note: This article includes information reported by Bethesda Magazine.
Live Poll
Should local governments prioritize investments to attract and expand the biotech industry in your area?
